Abstract: Human plasma protein binding (PPB) is an important pharmacokinetic property in drug design. Hologram quantitative structure-activity relationships (HQSAR) were conducted on a series of structurally diverse molecules with known PPB. The best statistical model (q 2 = 0.72, r 2 = 0.91) was used to predict the PPB of 62 test set compounds, and the predicted values were in good agreement with the experimental results.
Modern drug discovery tools such as combinatorial chemistry, high-throughput screening and molecular docking techniques have allowed the high-speed generation of leads as promising candidates for further drug development [1] . Researchers in the pharmaceutical and biotech industries have been developing tools over the past years to maximize the efficacy of drugs while minimizing toxicity. A drug intended for use in humans should have an ideal balance of efficacy and safety, as well as good pharmacokinetic properties [2] . Problems with drug candidates' absorption, distribution, metabolism and excretion (ADME), however, have been identified as a major cause of drug candidate failure in late stages of the drug development process [3, 4] . A variety of in silico ADME models is currently available due to a better appreciation that pharmacokinetic properties should be considered early in drug discovery programs. In vitro and in vivo ADME assays (e.g., Caco-2, PAMPA, MDCK, assessment of absorption, metabolism studies) are relatively expensive in terms of resources, reagents and detection techniques [5] . Therefore, in silico methods have emerged during the past decade as a powerful strategy for the modeling and prediction of human ADME properties [6] .
One major ADME property is the absorption of a drug candidate into the body. The absorption characteristic of an orally-administered drug is typically related to the drug's permeability -its ability to cross intestinal cell barriers before being distributed throughout the body toward the site of action. Plasma protein binding (PPB) plays a crucial role in drug design, determining the fraction of bioavailable free drug distributed through the various tissues [7] . A number of acidic drugs have high affinity for sites on blood proteins, particularly albumin, whereas the main binding protein for many basic drugs is alpha-1-acid glycoprotein (AGP) [8] . PPB of drugs is expressed as percentage of total drug that is bound. Prediction of the extent to which a molecule binds to plasma proteins is a critical phase of drug development because it influences human metabolism, clearance, and drug safety [9] .
Quantitative structure-activity relationships (QSAR) employing both classical and modern technologies have proved useful in a large number of settings [10, 11] . QSAR is a technology that generates descriptors based on molecular structures and uses computational algorithms to relate the key descriptors to the dependent property value of interest [12] . It is therefore possible to match these unique characteristics to pharmacokinetic properties due to large data sets of relevant properties that have become available over the past few years [13, 14] . In the present work, we have organized a data set of 312 structurally diverse molecules with known human PPB [15, 16] , and used the data to create predictive 2D QSAR models, employing the hologram QSAR (HQSAR) method [17] . Compounds whose PPB is strongly dose dependent were not included in the data set. Data set compounds containing one asymmetric (chiral) center, for which the corresponding PPB value was reported for the racemate, were treated as separate drugs (individual enantiomers) and modeled accordingly. The highly diverse compounds in the data set belong to a variety of therapeutic classes, including antiviral, antibacterial, anti-inflammatory, antipsychotic, antifungal, antihypertensive, antidepressant, immunosuppressive, analgesic, antineoplastic and antilipemic, among several others. PPB expressed as percentage was used for modeling purposes.
The data set was divided into training and test sets, containing 250 (001-250, Table 3 ) and 62 compounds (251-312, Table 3 ), respectively. The compounds of both training and test sets were carefully selected in order to ensure appropriate property coverage over the entire range of values (1-99.9%). A statistical cluster analysis carried out with Tsar 3D version 3.3 (Accelrys, San Diego, USA) employing the complete linkage clustering method (Euclidean distances) with no standardization showed that the composition of both training and test sets is representative of the whole data set. The HQSAR modeling analyses, calculations and visualizations were performed using the SYBYL 7.3 package (Tripos Inc., St. Louis, USA) as previously described [18] [19] [20] [21] [22] . Briefly, HQSAR requires only 2D structures and the property value of interest as inputs. In this method, each molecule in the data set is broken down into several unique structural fragments, which are then arranged to form a molecular hologram, an extended form of fingerprint that encodes all possible molecular fragments (i.e., linear, branched, and overlapping) and maintains a count of the number of occurrences of each fragment. Incorporation of information about each fragment, and each of its constituent sub-fragments, implicitly encodes 3D structural information such as hybridization and chirality. With the transformation of the chemical representation of a molecule into its corresponding molecular hologram, this method requires no explicit 3D information for the ligands (e.g., determination of 3D structure, putative binding conformations, and molecular alignment) [19] . HQSAR models can be affected by a number of parameters concerning hologram generation: hologram length, fragment size, and fragment distinction [20, 21] . Several combinations of fragment distinction were considered during the QSAR modeling runs, using a standard default series of hologram lengths. The influence of different fragment sizes was also investigated. The patterns of fragment counts from the training set molecules were then related to the experimental plasma protein binding data using the full cross-validated r 2 (q 2 ) partial least squares (PLS) leave-oneout (LOO) method [18, 20] .
In particular, the molecular fragments of the compounds contained in the training set were obtained using the following fragment distinctions: atoms (A), bonds (B), connections (C), hydrogen atoms (H), chirality (Ch), and donor and acceptor (DA). Several combinations of these parameters were considered using the fragment size default (4-7) as showed in Table 1 Table 1 .
The statistical quality of the models was evaluated by their corresponding q 2 and r 2 values. The best statistical results were obtained using the fragment distinction A/B/C/Ch (model 4, q 2 = 0.54, r 2 = 0.87). The influence of different fragment sizes in the statistical parameters was further investigated for the best HQSAR model generated in Table 1 (model 4), and the results are summarized in Table 2 . Fragment size parameters control the minimum and maximum length of fragments to be included in the hologram fingerprint. The results show that the variation of the fragment size did provide a considerable improvement when compared to the results obtained using the fragment size default (4-7). The best statistical result (q 2 = 0.72, r 2 = 0.91) among all models was obtained with the fragment size 2-5, as shown in Table 2 .
As the molecular structure encoded within a 2D hologram is directly related to the property value of the training set molecules, the HQSAR model should be able to predict the PPB for new compounds from its fingerprint. The q 2 LOO procedure used may give a suitable representation of the internal consistency and predictive power of the models. However, the real predictive ability of the HQSAR model derived with the 250 training set molecules (fragment distinction: A/B/C/Ch; fragment size: 2-5, Table 2 ) was assessed by predicting PPB values of an external test set of 62 molecules (compounds 251-312, Table 3 ). Prior to prediction, the test set compounds were processed identically to the training set compounds as previously described. The external validation process can be considered the most valuable validation method as these compounds were completely excluded during the training of the model. The results are listed in Table 3 , and the graphic results simultaneously displayed in (Fig. 1) .
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The good agreement between experimental and predicted values for the test set compounds establishes the reliability of the constructed HQSAR model (r 2 pred = 0.86). From the moderate residual values, it can be seen that the HQSAR model obtained is quite reliable and should be useful to predict PPB values of novel structurally diverse compounds. Computational tools are integrated throughout the drug discovery process to fully meet the ADME throughput demands for the screening of large data sets of compounds, creating tools that are faster, simpler and more cost-effective than traditional experimental methods. PPB is an important pharmacokinetic property that has been attracting attention recently for the generation of predictive in silico models [23] [24] [25] [26] . In this work, we developed a simple useful model employing special molecular holograms for predicting the approximate PPB of chemically diverse compounds based on the molecular structures alone. Although such a model cannot completely replace in vitro and in vivo testing, it is a useful tool for rapidly screening compounds for their probable behavior, allowing early elimination of unfavorable candidates. In general, in silico ADME approaches face considerable challenges in drug design. PPB is a difficult property to measure because of the complexity of the underlying biological processes. These include the variability of the experimental data, determination of the standard error, standardization and validation of the massive amount of data that is generated, among others. However, it is important to note that the final HQSAR model described herein shows both good internal and external consistency, with substantial predictive power, and should be useful for the design of new drug candidates with improved pharmacokinetic properties.
